Bebtelovimab a humanized IgG1-λ2 antibody targeting to SARS-CoV-2, especially COVID-19. Bebtelovimab potently neutralizes SARS-CoV-2 variants, and inhibits COVID-19 with mild-to-moderate efficacy[1][2].
References
[1] Shertel T, et al. Bebtelovimab for Treatment of COVID-19 in Ambulatory Solid Organ Transplant Recipients. Transplantation. 2022 Oct 1;106(10):e463-e464. DOI:10.1097/TP.0000000000004278 [2] Bebtelovimab. IMGT/mAb-DB.
